Evidence map›Paper›PMID 27506545›Full record

ArticleRespiratory research2016

High resolution metabolomics to discriminate compounds in serum of male lung cancer patients in South Korea.

Aryo D Pamungkas, Changyoung Park, Sungyong Lee, Sun Ha Jee, Youngja H Park

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment.Metabolomics : Official journal of the Metabolomic Society · 2018
    Article
  11. Increased urinary l-histidine in patients with asthma-COPD overlap: a pilot study.International journal of chronic obstructive pulmonary disease · 2018
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Aryo D PamungkasMetabolomics Laboratory, College of Pharmacy, Korea University, Sejong, 30019, Korea.
Changyoung ParkMetabolomics Laboratory, College of Pharmacy, Korea University, Sejong, 30019, Korea.
Sungyong LeeKorea University Guro Hospital 148, Gurodong-ro, Guro-gu, Seoul, 08308, Korea.
Sun Ha JeeDepartment of Epidemiology and Health Promotion and Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, 03722, Korea.
Youngja H ParkMetabolomics Laboratory, College of Pharmacy, Korea University, Sejong, 30019, Korea. yjhwang@korea.ac.kr.
Korea University · KRKorea Health Promotion Institute · KRKorea University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe cancer death rate escalated during 20th century. In South Korea, lung cancer is expected to contribute 12,736 deaths in men, the highest amount among all cancers. Several risk factors may increase the chance to acquiring lung cancer, with mostly related to exogenous compounds found in cigarette smoke and synthetic manufacturing materials. As the mortality rate of lung cancer increases, deeper understanding is necessary to explore risk factors that may lead to this malignancy. In this regard, this study aims to apply high resolution metabolomics (HRM) using LC-MS to detect significant compounds that might contribute in inducing lung cancer and find the correlation of these compounds to the subjects' smoking habit.

methodsThe comparison was made between healthy control and lung cancer groups for metabolic differences. Further analyses to determine if these differences are related to tobacco-induced lung cancer (past-smoker control vs. past-smoker lung cancer patients (LCPs) and non-smoker control vs. current-smoker LCPs) were selected. The univariate analysis was performed, including a false discovery rate (FDR) of q = 0.05, to determine the significant metabolites between the analyses. Hierarchical clustering analysis (HCA) was done to discriminate metabolites between the control and case subjects. Selected compounds based on significant m/z features of human serum then experienced MS/MS examination, showing that for many m/z, the patterns of ion dissociation matched with standards. Then, the significant metabolites were identified using Metlin database and features were mapped on the human metabolic pathway mapping tool of the Kyoto Encyclopedia of Genes and Genomes (KEGG).

resultsUsing metabolomics-wide association studies, metabolic changes were observed among control group and lung cancer patients. Bisphenol A (211.11, [M + H-H2O](+)), retinol (287.23, [M + H](+)) and L-proline (116.07, [M + H](+)) were among the significant compounds found to have contributed in the discrimination between these groups, suggesting that these compounds might be related in the development of lung cancer. Retinol has been seen to have a correlation with smoking while both bisphenol A and L-proline were found to be unrelated.

conclusionsTwo potential biomarkers, retinol and L-proline, were identified and these findings may create opportunities for the development of new lung cancer diagnostic tools.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesChromatography, LiquidCluster AnalysisHumansLung NeoplasmsMaleMetabolomicsMiddle AgedPredictive Value of TestsProlineRepublic of KoreaRisk FactorsSmokingSpectrometry, Mass, Electrospray IonizationBiomarkers, TumorProlineVitamin ABiomarkerBisphenol AHigh resolution metabolomicsLC-MSL-prolineLung cancerRetinol

Identifiers

PMID27506545
PMCPMC4977704
OpenAlexW2516450386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.